SAN DIEGO , Jan. 6, 2015 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE ; Sorrento), an oncology company developing new treatments for cancer and Conkwest, Inc., an immuno-oncology company developing proprietary Neukoplast ® , a Natural Killer (NK) cell-line based therapy, announced
CARDIFF-BY-THE-SEA, Calif.--( BUSINESS WIRE )--Conkwest, Inc., a clinical-stage immunotherapy company focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases, today announced that it has publicly
SAN DIEGO (December 29, 2014) – Conkwest, Inc. (the Natural Killer Cell Company of the West), an immuno-oncology company developing Neukoplast ® , a proprietary Natural Killer (NK) cell-line based therapy, announces the appointments of Robert Rosen and Henry Ji, Ph.D.
SAN DIEGO (December 24, 2014) —Conkwest, Inc., the N atural K iller Cell Co mpany of the West, developing the proprietary Natural Killer (NK) cell-line platform, Neukoplast ® as an immuno-oncology therapeutic, announces that Dr. Patrick Soon-Shiong, NantWorks founder, physician scientist and
CULVER CITY, Calif. --(BUSINESS WIRE)--Jun. 6, 2019-- NantKwest ( Nasdaq:NK ) today announced the appointment of Cheryl L. Cohen to the Board of Directors of NantKwest , effective immediately. “Cheryl is a proven business executive and highly experienced board member in both the biotechnology and
NK-92® Cell Based Bioanalytical Solutions are the Key to Optimizing R&D and Commercial Product Development Efforts for Monoclonal Antibodies, Bi-Specifics and Related Biological Products SAN DIEGO --(BUSINESS WIRE)--May 1, 2019-- Brink Biologics, Inc. , a NantKwest, Inc.
Cancer moonshot 2020 milestone: novel-novel combination of GPS Cancer guided cell based NK cell therapy and fusion proteins in QUILT trial CULVER CITY, Calif. & MIRAMAR, Fla. --(BUSINESS WIRE)--Oct. 4, 2016-- Altor BioScience Corporation (Altor), a leading developer of novel cytokine-based